GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commencement of dealings

19 Sep 2006 07:02

Quintessentially English PLC19 September 2006 QUINTESSENTIALLY ENGLISH PLC ("QE" OR THE "COMPANY") COMMENCEMENT OF DEALINGS Quintessentially English PLC (to be re-named Omega Diagnostics Group PLC)announces that it has completed inter alia the acquisition of Omega DiagnosticsLimited, a £1 million placing of new ordinary shares and an issue of warrants toexisting shareholders in the Company. Its ordinary shares are due to bereadmitted to trading on AIM today. Highlights • Acquisition of Omega Diagnostics Limited, a UK company specialising in in-vitro diagnostics test kits and related products through a distribution network in more than 100 countries • £1 million new equity (before expenses) raised via a cash placing of 50,000,000 New Ordinary Shares at 2p per share • Issue of 5,588,432 QE Warrants to existing Shareholders to subscribe for Ordinary Shares at an exercise price of 2p per share • Appointment of a new management team from Omega Diagnostics Limited: Andrew Shepherd, Chief Executive, Kieron Harbinson, Finance Director, David Evans, Non-executive Chairman; Michael Gurner continues as a Non-executive Director • The Acquisition furthers Omega's strategy to become a leading in-vitro diagnostics company - its strategy is to grow through selective acquisitions Andrew Shepherd, Chief Executive, commented: "The purchase of Omega Diagnostics Limited continues our aim to acquirecompanies within the medical diagnostics sector and positions us as a key playerin the in-vitro diagnostics kit market. Our strategy is to grow by acquisitionand to build our portfolio of products which we are already distributingthroughout the UK and in over 100 countries worldwide." On completion, the Company will be paying a maximum consideration of £3 millionof which approximately £1.2 million will be satisfied by the issue of 60,600,000 New Ordinary Shares and the balance of up to approximately £1.8 million as deferred consideration to be satisfied by way of up to 89,400,000 Earn Out Shares at a minimum issue price of 2p per share subject to certain earn out targets being met for the financial year ending 31 March 2008. Immediately following admission, the issued share capital of the Company will be 121,776,865 Ordinary Shares. For further information, please contact: Quintessentially English PLC (to be re-named Omega Diagnostics Group PLC) - 01259 763 030 Andrew ShepherdChief Executive Kieron HarbinsonFinance Director City Financial Associates Limited - 020 7090 7800 Barry SaintDirector END This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd May 202012:30 pmRNSExercise of Options and TVR
15th May 202011:05 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
13th May 20202:00 pmRNSPrice Monitoring Extension
7th May 20208:15 amRNSExercise of Options and TVR
6th May 202011:00 amRNSPrice Monitoring Extension
4th May 202011:00 amRNSExercise of Options and TVR
1st May 20202:30 pmRNSHolding(s) in Company
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202012:00 pmRNSExercise of Options and TVR
29th Apr 20205:37 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSHolding(s) in Company
28th Apr 20205:43 pmRNSHolding(s) in Company
28th Apr 20207:00 amRNSVISITECT® CD4 Advanced Disease - supply agreement
27th Apr 20204:42 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSCE-Mark of COVID-19 ELISA antibody test
24th Apr 202011:00 amRNSPrice Monitoring Extension
20th Apr 20202:05 pmRNSSecond Price Monitoring Extn
20th Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20201:24 pmRNSHolding(s) in Company
20th Apr 20201:23 pmRNSHolding(s) in Company
20th Apr 20207:00 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 MTA signed with Mologic Ltd
16th Apr 20205:40 pmRNSHolding(s) in Company
16th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20203:06 pmRNSHolding(s) in Company
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:36 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSCOVID-19 Consortium MOU
6th Apr 20209:30 amRNSVISITECT® CD4 Advanced Disease evaluation
6th Apr 20208:34 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSChinese Approval for Food Detective® test
2nd Apr 20207:00 amRNSTrading Update
24th Jan 20207:00 amRNSGrant of Options under Company EMI Plan
21st Jan 20203:24 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSExercise of Options and Total Voting Rights
17th Jan 202010:30 amRNSNigerian MOH approval for VISITECT CD4 350 test
8th Jan 202012:13 pmRNSHolding(s) in Company
16th Dec 20194:05 pmRNSDirector/PDMR Shareholding
9th Dec 20194:30 pmRNSHolding(s) in Company
2nd Dec 20199:00 amRNSGrant of Share Options
2nd Dec 20197:00 amRNSInterim Results
2nd Dec 20197:00 amRNSNigerian order for VISITECT® CD4
25th Nov 20197:00 amRNSUpdate on Allergy test menu
21st Nov 20197:00 amRNSInvestor results briefing
22nd Oct 201911:39 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.